Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and accessibility remain potential challenges in the ex vivo CAR-T approach. The prospect of an in vivo CAR-T cell therapy, without the need for patient cell isolation, cell culturing, and the safety risks associated with preconditioning regimens, remains a therapeutic goal. Orna Therapeutics’ panCAR™ combines a synthetic, circular, coding RNA platform (oRNA®) and proprietary immunotropic lipid nanoparticle (LNP) to drive CAR expression on the surface of immune effector cells after in vivo administration, with a potential to provide a transient, re-dosable, and scalable immune cell therapy without the need for preconditioning lymphodepletion. Methods: anti-CD19 panCAR™ is a non-viral platform combining anti-CD19 CAR expressing oRNA with a proprietary immunotropic LNP. Anti-CD19 panCAR was evaluated for expression in T cells and depletion of target B cells in vitro and in vivo in humanized CD34+ models upon intravenous injection. In a humanized model of lupus, anti-CD19 panCAR was dosed four times weekly, B cell levels and anti-double stranded DNA (anti-dsDNA) titers were evaluated. In cynomolgus macaques, anti-CD19 panCAR was dosed intravenously twice three days apart (Q3Dx2) at three doses levels (0.1, 0.5, and 1mpk). B cell levels were then evaluated in periphery and in lymphoid tissues by flow cytometry. Results: With anti-CD19 panCAR oRNA-LNP, high surface expression of anti-CD19 CAR was observed in a dose-dependent manner and was maintained over 96 hours on human and NHP immune cells in vitro. Furthermore, CAR-mediated cytotoxicity was observed for T cells from both species, killing CD19-expressing cell lines. In the humanized mouse model, anti-CD19 CAR oRNA-LNP when administered intravenously showed significant B cell reductions in peripheral blood, spleen, and bone marrow at 24 hours (55-95%) and sustained depletion 7 days after a single dose. The functional activity of anti-CD19 panCAR can be adjusted by the dose level and dose number administered, demonstrating the tunability of the platform. in vivo panCAR, injected in a humanized mouse model of lupus, showed complete reduction of B cells accompanied by anti-dsDNA titer reduction. While mice receiving rituximab exhibited reduced B cell numbers, the depletion did not correlate with reduced anti-dsDNA titers. Finally, in NHPs, our cross-reactive anti-CD19 compound showed complete ( >98%) and sustained depletion of B cells in peripheral blood two weeks after the last dose and showed robust depletion in the spleen ( >99%), lymph nodes ( >97%), and bone marrow ( >96%) three days after the last dose. Conclusion: Our platform provides a non-viral, transient, tunable, and scalable approach without the need for preconditioning lymphodepletion that shows robust activity in vitro and in vivo. In NHPs intravenous dosing resulted in deep B cell depletion in peripheral blood and lymphoid tissues. Collectively, our pre-clinical data demonstrates the potential of Orna’s in vivo panCAR therapy to treat B cell mediated autoimmunity.
